Albright Hereditary Osteodystrophy

To find patient care programs and faculty treating albright hereditary osteodystrophy at Kennedy Krieger Institute, please see the right-hand column below. Additional helpful information, including definitions, symptoms, Institute press releases, Potential magazine articles, and other resources outside the Institute, have also been provided for readers on this page.

Albright Hereditary Osteodystrophy Overview:

Albright hereditary osteodystrophy (termed AHO) is a rare genetic condition characterized by short stature, bone and tooth abnormalities and cognitive/behavioral problems. Patients with this condition often have bony deposits under the skin. AHO contains two sub-types: pseudohypoparathyroidism type 1a, characterized by hormonal problems and severe obesity, and pseudopseudohypoparathyroidism, characterized by normal hormonal function and usually normal weight. Dr. Germain-Lee has found that growth hormone deficiency occurs in approximately two-thirds of patients with pseudohypoparathyroidism type 1a. For the past several years, she has been conducting clinical trials in those patients with growth hormone deficiency to determine whether growth hormone treatment can improve height in children and improve other physical and psychological effects of growth hormone deficiency in patients of all ages, such as obesity, elevated lipid levels, osteoporosis, fatigue and reduced sense of well-being. The preliminary results of this trial are promising and provide the opportunity to improve the routine standard of care in patients with AHO. The trial is being expanded to include children with AHO who are not growth hormone deficient in order to evaluate whether an increase in height can occur in this group as well.